CiVi Biopharma has appointed Shalom “Shal” Jacobovitz as chief executive officer and a director on their Board of Directors effective February 2, 2018.  

Mr. Jacobovitz most recently served as chief executive officer of the American College of Cardiology, and before that, as president of Actelion Pharmaceuticals.

“We are extremely pleased to welcome Shal to CiVi Biopharma,” said Aaron Davis, chief executive officer of Boxer Capital, and executive chairman of CiVi Biopharma.  “As CiVi prepares to dose the first patient in January 2018 in its phase I clinical trial for the Company’s lead product candidate, CiVi007, a long-acting PCSK9 inhibitor being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease, Shal’s vast knowledge of the treatment landscape for cardiovascular diseases will play a critical role in the Company’s future development plans.”